Personalized cancer vaccines from Moderna and Merck have added more than $50 billion in combined market value for the two drugmakers. That momentum is opening a less obvious investing lane in the diagnostics work behind every dose.
The vaccines depend on genetic sequencing to identify the…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.